1. Search Result
Search Result
Targets Recommended: APC
Results for "

promoting

" in MCE Product Catalog:

266

Inhibitors & Agonists

5

Screening Libraries

2

Dye Reagents

3

Biochemical Assay Reagents

29

Peptides

84

Natural
Products

1

Recombinant Proteins

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Area
  • HY-P0306
    Fibronectin Adhesion-promoting Peptide

    Heparin Binding Peptide

    Peptides Cardiovascular Disease
    Fibronectin Adhesion-promoting Peptide (Heparin Binding Peptide) is one of the heparin-binding amino acid sequences found in the carboxy-terminal heparin-binding domain of fibronectin. It promotes assembly of mesenchymal stem cell (MSC) spheroids into larger aggregates. Fibronectin Adhesion-promoting Peptide directly promotes the adhesion, spreading, and migration of endothelial cells by reacting with heparin binding domains of cells.
  • HY-P0306A
    Fibronectin Adhesion-promoting Peptide TFA

    Heparin Binding Peptide TFA

    Peptides Cardiovascular Disease
    Fibronectin Adhesion-promoting Peptide (Heparin Binding Peptide) is one of the heparin-binding amino acid sequences found in the carboxy-terminal heparin-binding domain of fibronectin. It promotes assembly of mesenchymal stem cell (MSC) spheroids into larger aggregates. Fibronectin Adhesion-promoting Peptide directly promotes the adhesion, spreading, and migration of endothelial cells by reacting with heparin binding domains of cells.
  • HY-P0267
    Melanotan (MT)-II

    Peptides Neurological Disease
    Melanotan (MT)-II, a synthetic melanocortin receptor agonist, is an injectable peptide hormone used to promote tanning.
  • HY-P1589
    β-catenin peptide

    Peptides Cancer
    β-catenin peptide is a 8-aa peptide, and can promote thymocyte positive selection.
  • HY-A0162A
    Quinupristin mesylate

    Bacterial Infection
    Quinupristin mesylate is a streptogramin antibiotic. Quinupristin mesylate blocks peptide bond synthesis to prevent the extension of polypeptide chains and promote the detachment of incomplete protein chains in the bacterial ribosomal subunits.
  • HY-P0170
    TB500

    Peptides Metabolic Disease
    TB500 is a synthetic version of an active region of thymosin β4. TB500 is claimed to promote endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, collagen deposition and decrease inflammation.
  • HY-P1824
    C-Reactive Protein (CRP) (201-206)

    Peptides Inflammation/Immunology Cardiovascular Disease
    C-Reactive Protein (CRP) 201-206 is the 201-206 fragment of C-Reactive Protein. C-Reactive Protein (CRP), the prototypic marker of inflammation, is a cardiovascular risk marker and may promote atherogenesis.
  • HY-P1836
    C-Reactive Protein (CRP) (77-82)

    Peptides Inflammation/Immunology Cardiovascular Disease
    C-Reactive Protein (CRP) 77-82 is the 77-82 fragment of C-Reactive Protein. C-Reactive Protein (CRP), the prototypic marker of inflammation, is a cardiovascular risk marker and may promote atherogenesis.
  • HY-P1823
    C-Reactive Protein (CRP) (174-185)

    Peptides Inflammation/Immunology Cardiovascular Disease
    C-Reactive Protein (CRP) 174-185 is the 174-185 fragment of C-Reactive Protein. C-Reactive Protein (CRP), the prototypic marker of inflammation, is a cardiovascular risk marker and may promote atherogenesis.
  • HY-P2352
    Fetuin, Fetal Bovine Serum

    Peptides Metabolic Disease
    Fetuin, Fetal Bovine Serum is a liver-secreted 64 kDa plasma glycoprotein isolated from fetal bovine serum. Fetuin, Fetal Bovine Serum inhibits trypsin activity and promote cellular attachment, growth, and differentiation.
  • HY-P2633
    Dentonin

    AC-100

    Peptides Metabolic Disease
    Dentonin (AC-100) is a synthetic fragment derived from MEPE. Dentonin enhances osteogenesis by promoting osteoprogenitor adhesion and facilitates immature adherent cells survival. Dentonin has no significant effect to mature osteoblasts. Dentonin can be used for the research of phosphate homeostasis and bone metabolism.
  • HY-P1740
    RGD peptide (GRGDNP)

    Integrin Apoptosis Inflammation/Immunology
    RGD peptide (GRGDNP) acts as an inhibitor of integrin-ligand interactions and plays an important role in cell adhesion, migration, growth, and differentiation. RGD peptide (GRGDNP) promote apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing.
  • HY-19884
    Relamorelin

    RM-131; BIM-28131

    GHSR Metabolic Disease
    Relamorelin (RM-131), a Ghrelin analog, is a potent ghrelin receptor agonist, with a Ki of 0.42 nM for GHS-1a. Relamorelin can promote food intake and adiposity in mice. Relamorelin can be used for the research of cachexia, gastroparesis, and gastric/intestinal dysmobility disorders.
  • HY-19884A
    Relamorelin acetate

    RM-131 acetate; BIM-28131 acetate

    GHSR Metabolic Disease
    Relamorelin (RM-131) acetate, a Ghrelin analog, is a potent ghrelin receptor agonist, with a Ki of 0.42 nM for GHS-1a. Relamorelin acetate can promote food intake and adiposity in mice. Relamorelin acetate can be used for the research of cachexia, gastroparesis, and gastric/intestinal dysmobility disorders.
  • HY-P1740A
    RGD peptide (GRGDNP) (TFA)

    Integrin Apoptosis Inflammation/Immunology Cancer
    RGD peptide (GRGDNP) (TFA) acts as an inhibitor of integrin-ligand interactions and plays an important role in cell adhesion, migration, growth, and differentiation. RGD peptide (GRGDNP) (TFA) promote apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing.
  • HY-P2080
    GIP (1-30) amide,human

    Insulin Receptor Metabolic Disease
    GIP (1-30) amide,human is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions. GIP (1-30) amide,human dose-dependently promotes insulin secretion over the range 10 -9-10 -6 M.
  • HY-P2080B
    GIP (1-30) amide,human acetate

    Insulin Receptor Metabolic Disease
    GIP (1-30) amide,human acetate is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions. GIP (1-30) amide,human acetate dose-dependently promotes insulin secretion over the range 10 -9-10 -6 M.
  • HY-P2633A
    Dentonin TFA

    AC-100 TFA

    Peptides Metabolic Disease
    Dentonin TFA (AC-100 TFA) is a synthetic fragment derived from MEPE. Dentonin TFA enhances osteogenesis by promoting osteoprogenitor adhesion and facilitates immature adherent cells survival. Dentonin TFA has no significant effect to mature osteoblasts. Dentonin TFA can be used for the research of phosphate homeostasis and bone metabolism.
  • HY-P2264
    KYL peptide

    Ephrin Receptor Inflammation/Immunology
    KYL peptide, an antagonistic peptide, selectively targets EphA4 receptor. KYL peptide binds to the ligand-binding domain of EphA4, effectively alleviates Aβ-induced synaptic dysfunction and synaptic plasticity defects in AD mice. KYL peptide can promote nerve regeneration after injury and modulating immune responses.
  • HY-P1131A
    M617 TFA

    Peptides Cardiovascular Disease
    M617 TFA is a selective galanin receptor 1 (GAL1) agonist, with Kis of 0.23 and 5.71 nM for GAL1 and GAL2, respectively. M617 TFA, acting through its central GAL1, can promote GLUT4 expression and enhance GLUT4 content in the cardiac muscle of type 2 diabetic rats.
  • HY-P1376A
    G-Protein antagonist peptide TFA

    mAChR Adrenergic Receptor Endocrinology
    G-Protein antagonist peptide TFA is a truncated substance P-related peptide, competes with receptor for G protein binding. G-Protein antagonist peptide TFA inhibits the activation of Gi or Go by M2 muscarinic cholinergic receptor (M2 mAChR) or of Gs by beta-adrenergic receptor in the reconstituted phospholipid vesicles, assayed by receptor-promoted GTP hydrolysis.
  • HY-P0093
    Sincalide

    Cholecystokinin octapeptide; CCK-8; SQ19844

    Peptides Cancer
    Sincalide (Cholecystokinin octapeptide) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. Sincalide ammonium is an agent that promotes gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. The hepatobiliary physiologic effect of Sincalide ammonium is to increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum.
  • HY-P0093A
    Sincalide ammonium

    Cholecystokinin octapeptide ammonium; CCK-8 ammonium; SQ19844 ammonium

    Peptides Cancer
    Sincalide ammonium (Cholecystokinin octapeptide ammonium) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. Sincalide ammonium is an agent that promotes gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. The hepatobiliary physiologic effect of Sincalide ammonium is to increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum.
  • HY-P3245
    HXR9

    Apoptosis Cancer
    HXR9 is a cell-permeable peptide and a competitive antagonist of HOX/PBX interaction. HXR9 antagonizes the interaction between HOX and a second transcrip-tion factor (PBX), which binds to HOX proteins in paralogue groups1 to 8. HXR9 selectively decreases cell proliferation and promotes apoptosis in cells with a high level of expression of the HOXA/PBX3 genes, such as MLL-rearranged leukemic cells.
  • HY-P0172A
    ATI-2341 TFA

    CXCR Cancer Inflammation/Immunology Endocrinology
    ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4), which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs).
  • HY-P0172
    ATI-2341

    CXCR Inflammation/Immunology Endocrinology Cancer
    ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4), which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs).
  • HY-P2196A
    ELA-32(human) TFA

    Peptides
    ELA-32(human) TFA is a potent, high affinity apelin receptor agonist (IC50=0.27 nM; Kd=0.51 nM). ELA-32(human) TFA exhibits no binding GPR15 and GPR25. ELA-32(human) TFA activates the PI3K/AKT pathway and promotes self-renewal of hESCs via cell-cycle progression and protein translation. ELA-32(human) TFA also potentiates the TGFβ pathway, priming hESCs toward the endoderm lineage. ELA-32(human) TFA stimulates angiogenesis in HUVEC cells.
  • HY-P2141
    TRV-120027

    Angiotensin Receptor Cardiovascular Disease
    TRV120027, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages ß-arrestins while blocking G-protein signaling. TRV120027 induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 has the potential for the acute decompensated heart failure (ADHF) treatment.
  • HY-P2141A
    TRV-120027 TFA

    Angiotensin Receptor Cardiovascular Disease
    TRV120027 TFA, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages ß-arrestins while blocking G-protein signaling. TRV120027 TFA induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 TFA inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 TFA has the potential for the acute decompensated heart failure (ADHF) treatment.